ImmunityBio (IBRX) News Today $2.78 -0.11 (-3.81%) Closing price 04:00 PM EasternExtended Trading$2.74 -0.03 (-1.26%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday?April 15 at 4:43 AM | msn.comImmunityBio, Inc. (NASDAQ:IBRX) Stake Increased by Vanguard Group Inc.Vanguard Group Inc. raised its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,328,229 shares of the company's stock after acquiring an additiApril 14 at 3:21 AM | marketbeat.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Wednesday.April 11, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.1% - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Down 5.1% - What's Next?April 10, 2025 | marketbeat.comImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comImmunityBio announces $75M in equity financing with institutional investorApril 9, 2025 | markets.businessinsider.comImmunityBio Secures $75 Million in Direct OfferingApril 8, 2025 | tipranks.comImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional InvestorApril 8, 2025 | businesswire.comPomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. SecuritiesApril 7, 2025 | prnewswire.comImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial LaunchApril 7, 2025 | businesswire.comImmunityBio: Taking Care Of BusinessApril 3, 2025 | seekingalpha.comD. Boral Capital Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)D. Boral Capital reiterated a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a research note on Monday.April 1, 2025 | marketbeat.comWhy ImmunityBio Inc. (IBRX) Went Up Last Week?March 30, 2025 | msn.comCorient Private Wealth LLC Has $569,000 Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)Corient Private Wealth LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 50.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 222,380 shares of the company's stock after selling 224,080 shareMarch 30, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 8.9% - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Down 8.9% - What's Next?March 29, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 10.6% - What's Next?ImmunityBio (NASDAQ:IBRX) Shares Up 10.6% - Here's What HappenedMarch 28, 2025 | marketbeat.comTop 10 Penny Stocks That Will SkyrocketMarch 27, 2025 | insidermonkey.comImmunityBio to Host Investor DayMarch 26, 2025 | businesswire.comIs ImmunityBio, Inc. (NASDAQ:IBRX) The Top Penny Stock That Will Skyrocket?March 25, 2025 | msn.comClearwater Capital Advisors LLC Acquires 363,870 Shares of ImmunityBio, Inc. (NASDAQ:IBRX)Clearwater Capital Advisors LLC grew its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 75.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 846,419 shares of the company's stock after acquiring an additMarch 18, 2025 | marketbeat.comImmunityBio (IBRX) Expected to Announce Earnings on TuesdayImmunityBio (NASDAQ:IBRX) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 16, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 2.9% - What's Next?ImmunityBio (NASDAQ:IBRX) Trading Down 2.9% - Here's WhyMarch 15, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a research note on Thursday.March 14, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 4.4% - Should You Buy?ImmunityBio (NASDAQ:IBRX) Trading Up 4.4% - Should You Buy?March 14, 2025 | marketbeat.comImmunityBio announces 1st dosing of rBCG in U.S. and 60 sites pendingMarch 13, 2025 | markets.businessinsider.comImmunityBio, Inc. (IBRX): Among the Stocks Under $10 With High Upside PotentialMarch 12, 2025 | insidermonkey.comQ1 Earnings Forecast for ImmunityBio Issued By HC WainwrightImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of ImmunityBio in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Maldonado forecasts that the company will pMarch 11, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on ImmunityBio in a report on Thursday. They issued a "buy" rating and a $8.00 price objective for the company.March 7, 2025 | marketbeat.comImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial MomentumMarch 7, 2025 | seekingalpha.comImmunityBio initiated with a Buy at H.C. WainwrightMarch 6, 2025 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Up 6.8% on Strong EarningsImmunityBio (NASDAQ:IBRX) Trading Up 6.8% After Earnings BeatMarch 5, 2025 | marketbeat.comWhy ImmunityBio Inc. (IBRX) Crashed on MondayMarch 4, 2025 | msn.comImmunityBio stock rises on Q4 earnings beat, revenue growthMarch 4, 2025 | investing.comImmunityBio (NASDAQ:IBRX) Shares Gap Down - Should You Sell?ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Time to Sell?March 3, 2025 | marketbeat.comImmunityBio reports Q4 EPS (9c), consensus (13c)March 3, 2025 | markets.businessinsider.comImmunityBio: Q4 Earnings SnapshotMarch 3, 2025 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Announces Earnings Results, Beats Estimates By $0.11 EPSImmunityBio (NASDAQ:IBRX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11.March 3, 2025 | marketbeat.comImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024March 3, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Should You Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's WhyMarch 1, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $30.00 price target on shares of ImmunityBio in a report on Friday.March 1, 2025 | marketbeat.comImmunityBio Shares Up, FDA Gives RMAT Designation for Treatment of Lymphopenia in Cancer PatientsFebruary 28, 2025 | marketwatch.comImmunityBio stock climbs 10% on FDA RMAT designationFebruary 28, 2025 | msn.comImmunityBio receives FDA RMAT designation for AnktivaFebruary 28, 2025 | markets.businessinsider.comImmunityBio receives FDA RMAT designation for AnktivaFebruary 28, 2025 | markets.businessinsider.comIMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmFebruary 27, 2025 | globenewswire.comImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic CancerFebruary 27, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Trading Down 8.1% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Trading Down 8.1% - Here's WhyFebruary 21, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - Time to Buy?ImmunityBio (NASDAQ:IBRX) Sees Strong Trading Volume - Here's What HappenedFebruary 20, 2025 | marketbeat.comWhy ImmunityBio (IBRX) Is Surging TodayFebruary 20, 2025 | msn.comWhy ImmunityBio, Inc. (IBRX) Went Up On Wednesday?February 20, 2025 | msn.com Remove Ads Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.630.78▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼94▲IBRX Articles Average Week Remove Ads Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News QGEN News VTRS News ROIV News LNTH News RVMD News BBIO News TGTX News LEGN News TLX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
